Rock Creek Pharma (RCPI) Completes Anatabine Citrate Phase 1 Trial in U.K.

Go back to Rock Creek Pharma (RCPI) Completes Anatabine Citrate Phase 1 Trial in U.K.

Rock Creek Pharmaceuticals Announces Successful Completion of Phase I Clinical Trial to Evaluate Oral Formulations of its Lead Compound, Plans to Conduct Proof-of-Concept Trial in Subjects with Mild t

October 15, 2015 9:43 AM EDT

SARASOTA, Fla., Oct. 15, 2015 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a clinical stage drug development company focused on the application of its lead compound being developed to treat chronic inflammatory conditions, announced today the successful completion of its three part Phase I clinical trial conducted in the United Kingdom (UK).  The overall objective of the Phase I trial was to evaluate safety, tolerability and pharmacokinetic (PK) profiles of different formulations of the Company's lead compound, Anatabine Citrate, in healthy... More

Rock Creek Pharmaceuticals Announces Institutional Financing with Issuance of $20 Million of Convertible Notes

October 15, 2015 9:02 AM EDT

SARASOTA, Fla., Oct. 15, 2015 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a clinical stage, drug development company which is focused on the application of its lead compound being developed to treat chronic inflammatory conditions, announced today that the Company has entered into an agreement with two healthcare focused, institutional investors to issue $20 million of senior convertible notes.

Dr. Michael Mullan, (MBBS, PhD), Chairman and... More